Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program. Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.

Novartis Venture Fund

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernseyâ€“based fund is advised by the Bellevue Asset Management Group, which has operations in CuraÃ§ao, Boston/USA and Kusnacht/Zurich, Switzerland.   BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Groupâ€™s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

BB Biotech Ventures

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

EQT Life Sciences

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.  JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Johnson & Johnson Development Corporation

Consort Medical is a leading global contract development and manufacturing organisation (CDMO), providing advanced delivery technologies, formulation and manufacturing solutions for drugs. Their customers include some of the world’s largest pharmaceutical companies. Optimising world-class drug delivery device development and manufacture, together with drug Active Pharmaceutical Ingredient (API) and finished dose formulation and manufacture, within the same Group streamlines and accelerates their pharmaceutical customers’ drug route to market. The Group is at the leading edge of innovation and is committed to investing in patient and customer driven innovation, with the potential to create new treatments, new markets and new opportunities. They  also continue to diversify into adjacent complementary markets and technologies which leverage their core competencies in drug formulation, manufacturing and delivery.

Consort Medical

YFM Equity Partners is an independent private equity business owned by its senior management and investment team. They invest up to £10 million of equity through offices in Leeds, London, Manchester, Birmingham and Sheffield.

YFM Equity Partners

RMI Partners is a venture company with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, the company makes global investments in a variety of therapeutic areas. RMI Partners is currently managing the venture fund Rusnano MedInvest, that is created to develop innovative projects in the field of medicine and pharmaceutics. RMI Partners portfolio includes companies from Russia, USA, UK, and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies.

RMI Partners

Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.

Global Life Science Ventures

Technology Venture Partners is venture capital firm investing in emerging technology companies in the South of the UK. TVP invests across a broad range of technology sectors including enterprise and infrastructure software, communications and networking, electronics, advanced materials, medical technology and healthcare IT. TVP portfolio companies include Atlas Genetics (point of care DNA based diagnostics for infectious diseases), Symetrica (radiation detection for security applications), Micrima (radiowave based imaging for breast cancer detection) and Dynmark (cloud based mobile messaging and analytics). Several of the TVP portfolio companies were originally spinouts from leading universities and research institutions located in the South of the UK.

Technology Venture Partners

Johnson & Johnson Innovation is a center for science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer, pharmaceutical, and medical devices and diagnostics sectors.’ The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more. They conduct their activities with the help of regional incubators, satellite operations, single bench tops, modular labs, office space for entrepreneurs, and a year-round curriculum focused on business and drug development. Johnson & Johnson Innovation is a subsidiary of [Johnson & Johnson](http://www.crunchbase.com/organization/johnson-johnson)  and its centers are located in Boston, California, London, and Shanghai.

Johnson & Johnson Robotics and Digital Solutions

Wondfo Biotech specializes in providing healthcare products and services. It is a biotech company that develops, manufactures, and markets a variety of rapid diagnostic tests. Its products are used in a clinical test, field test, and personal health management. Founded in 1992, Wondfo Biotech is headquartered in Guangzhou, China.

Wondfo Biotech

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed

ArrowMark Partners is an SEC-registered investment adviser. It aims to provide consistent, asymmetric, non-correlated, risk-adjusted returns by utilizing fundamental research across the capital structure. They are committed to compounding wealth by providing one-of-a-kind, client-driven, and absolute return solutions.

ArrowMark Partners

Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

Alta Life Sciences

Hildred Capital Partners, LLC is a family investment firm that invests in a broad range of securities, including equity and debt, across geographies and sectors, on both an active and passively managed basis. Hildred has a particular interest in private equity, including situations where the principals can apply their extensive management experience to help a company reach its full potential.

Hildred Capital Partners

Parian Global Management is an investment firm that seeks to invest in dynamic industries.

Parian Global Management

A premiere healthcare focused growth equity firm.

Hildred Capital Management, LLC

Binx Health

Binx Health is committed to broadening convenient and equitable access to healthcare. The company's point-of-care diagnostic solutions empower its partners to overcome traditional barriers to care, extend their outreach, and deliver exceptional patient experiences. The binx io point-of-care molecular platform marks a significant milestone as the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males (urine) and females (vaginal swabs). It delivers results comparable to those of central lab performance, typically within about thirty minutes.

Binx Health is a healthcare technology and diagnostics company focused on expanding access to convenient and equitable healthcare through innovative testing solutions. The company's primary offering is the Binx io, an FDA-cleared, CLIA-waived point-of-care molecular platform for rapid diagnosis of chlamydia and gonorrhea. This system can deliver results in about 30 minutes, enabling same-visit diagnosis and treatment in various clinical settings such as doctors' offices, urgent care clinics, and hospital emergency rooms. The Binx io platform is designed to be highly flexible and easy to use, collapsing the time between testing and treatment while the patient is still in the clinic.

Diagnostics company Binx Health banks $65M to drive growth of point-of-care testing

Mark Cuban Is Partnering With Binx Health To Increase Healthcare Access

imaware acquires binx health’s consumer testing business, becoming a leader in STI health screening

Governments Turn to binx health to Expand Testing Efforts for COVID-19

Amid National Surge in Sexually Transmitted Infections binx health Announces Launch of Reagent Rental Program for Decentralized, Rapid, Point-of-Care Testing Platform for Chlamydia and Gonorrhea

binx health Announces Strategic Supply Agreement with Afaxys to Expand Sexual Health Test Access to Thousands of Clinics Nationally

Redefining hospital care with the comfort of home

Hospital-at-Home

Binx Health Raises $65M in Series F Financing Round

Cardinal Health

A national distribution agreement with Cardinal Health to expand access to care with the CLIA-waived, FDA-cleared binx io® to improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG).

Binx Health is a healthcare technology and diagnostics company focused on expanding access to convenient and equitable healthcare through innovative testing solutions. The company's primary offering is the Binx io, an FDA-cleared, CLIA-waived point-of-care molecular platform for rapid diagnosis of chlamydia and gonorrhea. This system can deliver results in about 30 minutes, enabling same-visit diagnosis and treatment in various clinical settings such as doctors' offices, urgent care clinics, and hospital emergency rooms. The Binx io platform is designed to be highly flexible and easy to use, collapsing the time between testing and treatment while the patient is still in the clinic.
In addition to its point-of-care testing, Binx Health previously operated a consumer testing business that provided at-home testing services for various health conditions. However, in December 2023, this division was sold to Imaware, allowing Binx to focus solely on its point-of-care offerings. The company's technology aims to address the growing epidemic of sexually transmitted infections (STIs) by providing rapid, accurate testing that can lead to immediate treatment and potentially reduce infection spread.
Binx Health has established partnerships with major medical device distributors, including Cardinal Health, Fisher healthcare, McKesson, and Medline, to broaden its market reach. The company has also worked with state governments, including North Carolina and Maryland, to provide Covid-19 testing solutions during the pandemic. As of April 2024, Binx Health secured USD 65 million in series F financing to support its commercial growth and manufacturing scale. The company is actively expanding its testing capabilities, with plans to develop point-of-care diagnosis for trichomoniasis in the future.

<div>
 
 AdaptHealth is a network of full-service medical equipment companies that provides tailored products and services to enable patients to live their best lives at home rather than in hospitals. The company offers a wide range of medical equipment and supplies, including CPAP machines, oxygen units, walkers, and compression socks. AdaptHealth's business model focuses on delivering healthcare solutions that fit into patients' everyday lives, with offerings that span from doctor's prescriptions to doorstep delivery.
 
 
 
 
 The company emphasizes customer service and satisfaction as its primary concern, providing online support to answer questions and a team of customer service representatives to help patients choose the right supplies. AdaptHealth also offers fast and convenient shipping directly to patients' homes. In November 2020, AdaptHealth acquired New England Home Medical Equipment (NEHME), a leading supplier of continuous glucose monitoring (CGM) and diabetes management supplies in the New England and Northeastern US. NEHME generated net revenues of approximately USD 31 million for the twelve months ended September 30, 2020, contributing to AdaptHealth's expansion in the diabetes care sector.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 
 AdaptHealth serves a diverse range of patients with various medical needs, including those requiring CPAP machines for sleep apnea, oxygen therapy, mobility aids, and diabetes management supplies. The company's customer base includes individuals with chronic medical conditions who require ongoing support and medical equipment. Through its acquisition of NEHME, AdaptHealth expanded its reach to diabetes patients throughout New England and the Northeastern US.
 
</div>

AdaptHealth

DispatchHealth is a Denver-based healthcare company that provides comprehensive in-home medical care services across the US. Founded in 2013, the company aims to transform healthcare delivery by offering high-acuity care in the comfort of patients' homes. DispatchHealth's services include same-day urgent medical care, hospital alternative care, and recovery care. The company employs teams of emergency medicine and internal medicine trained professionals, including nurse practitioners, physician assistants, and emergency medical technicians, who are equipped with advanced medical tools and technologies to treat a wide range of conditions typically handled in emergency rooms or urgent care centers.
DispatchHealth's care model utilizes a proprietary technology platform that manages various aspects of the in-home care experience, including logistics, onboarding, risk stratification, care coordination, and analytics. This platform enables real-time data insights to improve patient outcomes. The company's services are designed to reduce unnecessary emergency room visits, hospital stays, and readmissions, resulting in significant cost savings for the healthcare system. As of December 2023, DispatchHealth reported treating more than one million patients across more than 30 states, leading to a 58% reduction in emergency room visits, an 8.5% 30-day hospital readmission rate, and nearly USD 1.5 billion in medical cost savings.
Key customers and partnerships
DispatchHealth has established partnerships with various healthcare stakeholders, including health plans, provider groups, health systems, employers, senior living facilities, and home health organizations. In May 2023, the company announced a collaboration with Included Health to enhance virtual-to-in-home care delivery, enabling Included Health's virtual primary care clinicians to coordinate with DispatchHealth's in-home clinical services.
DispatchHealth also formed a partnership with Instacart in January 2024 to address food insecurity among patients. This collaboration allows DispatchHealth's medical professionals to provide digital food stipends, offer medically tailored shopping lists, and send food directly to patients' homes.
In the Spokane area, DispatchHealth partnered with MultiCare Health System in August 2019 to improve healthcare access for at-risk patient populations. The company works with almost all major insurance companies, including Medicare and parts of Medicaid, to reduce the cost of care significantly.

DispatchHealth

Honor Technology, Inc. is a home care company that operates a technology-enabled platform to provide care services for older adults. Founded in 2014, Honor combines local care, 24/7 support, and advanced technology through its proprietary Honor Care Platform. This platform utilizes dynamic scheduling software and machine learning to optimize caregiver-client matching based on skills, commute times, and other factors. It also assists with caregiver recruiting, training, scheduling, and performance analysis.
In August 2021, Honor acquired Home Instead, one of the largest home care providers globally. This acquisition expanded Honor's reach significantly, with the combined company representing over USD 2.1 billion in revenue as of October 2021. Honor's technology aims to improve efficiency and care quality across its network of caregivers and partner agencies.
The company offers various services through different arms of its business. Honor Expert, launched in April 2022, is an online and mobile service that connects older adults and their families with resources, tools, and services related to aging and health issues. Honor also operates the Honor Care Network, which partners with independent home care agencies to provide back-office support, technology, and operational expertise in exchange for a share of revenue.
Key customers and partnerships
Honor has established partnerships with several national companies to enhance its service offerings. As of April 2022, Honor Expert had 14 national partners, including Amazon Business, Best Buy, SelectRX, and Freshly. These partnerships aim to provide users with access to a range of products and services addressing various aging-related needs.
The company's acquisition of Home Instead significantly expanded its customer base. Home Instead operates in 12 countries and has over 600 franchised locations in the US alone. This expansion has allowed Honor to serve clients across a wider geographic area and potentially develop contracts with national insurance carriers or major health systems.
Honor also partners with independent home care agencies through its Honor Care Network. These partnerships allow smaller agencies to benefit from Honor's technology and operational capabilities while maintaining their local presence and client relationships.

Honor

Alto Pharmacy is a digital pharmacy platform founded in 2015 by former Facebook engineers Jamie Karraker and Mattieu Gamache-Asselin. The company aims to simplify the prescription process and improve medication adherence through its technology-enabled solution. Alto's platform streamlines coordination between patients, doctors, and insurance companies, offering free same-day prescription delivery, lower costs on medications, and access to pharmacist support.
Alto's services include a mobile app for patients to manage their prescriptions, set reminders, and chat with pharmacists. The company also offers Alto Connect, a mobile app for doctors' offices to streamline prescription management and communication. Alto specializes in delivering medications for various conditions, including HIV, hepatitis C, asthma, rheumatology, and cardiology, among others.
As of 2022, Alto Pharmacy operates in 13 markets across the US, including major cities like San Francisco, Los Angeles, New York, and Houston. The company has experienced rapid growth, with its annual revenue reaching USD 700 million in 2022 and projections to cross the USD 1 billion mark by the end of that year. Alto has delivered over 4 million prescriptions to hundreds of thousands of patients and claims to have provided more than USD 120 million in savings to date.

Alto Pharmacy

LetsGetChecked is a healthcare solutions company that provides at-home diagnostic testing kits and virtual care services. Founded in 2015 by Peter Foley, the company offers over 30 different health tests covering areas such as sexual health, women's health, men's health, general wellness, and Covid-19. LetsGetChecked's testing process involves customers ordering a kit online, collecting their sample at home, and mailing it back to CLIA-certified and CAP-accredited laboratories for analysis. Results are typically available within 2-5 days through a secure online portal. The company utilizes biomarkers to analyze health conditions and employs highly accurate testing methods like NAAT PCR and electrochemiluminescence arrays for certain tests. In November 2023, LetsGetChecked achieved a significant milestone when the FDA granted marketing authorization for its Simple 2 Test, the first at-home test for chlamydia and gonorrhea. The company has expanded its services to include telehealth consultations and prescription delivery, aiming to provide a comprehensive healthcare solution. LetsGetChecked operates its own manufacturing facilities and laboratories, allowing for quality control throughout the testing process. As of 2024, the company has delivered over 7 million tests and serves more than 30 markets globally.
Key customers and partnerships
LetsGetChecked has partnered with over 300 corporate customers to provide testing services and biometric screening solutions. The company has also collaborated with major retailers and healthcare providers. In 2023, LetsGetChecked announced a partnership with PatientsLikeMe (PLM), a community health network, to offer PLM members access to testing at discounted prices. Additionally, the company has worked with UnitedHealthcare, Optum, HSA Store, FSA Store, and CVS Pharmacy. LetsGetChecked's services are available nationwide in the US, the UK, and most EU countries, with co-headquarters in Dublin and New York.

LetsGetChecked

Digital platforms that connect patients with in-person medical care providers in the comfort of their homes and support care delivery

Platforms enabling healthcare providers to order in-home therapies, durable medical equipment, and provide virtual acute care services

Companies offering a full-stack of in-home medical services including health evaluations, virtual and in-person visits for a variety of needs, and care coordination by leveraging data analytics

Platforms providing accessible lab testing solutions for a range of conditions, allowing patients to conveniently perform tests in their own homes

Digital pharmacies that deliver prescription medications directly to patients' homes and platforms that help track and manage medication adherence

Solutions enabling hospitals to establish hospital-at-home programs and providing workflow management tools for home care providers

Binx Health

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless